Fig. 5

Brivaracetam and lacosamide treatments exert their anti-proliferative effect in part trough miR-195-5p. a-b Proliferation assay (a) and viability assay b in U87MG cells transfected with miR-195-5p mimic or control. Cells were collected and counted at the indicated time points. c Distribution of U87MG cells in the different phases of the cell cycle. Data are expressed as percentage of cell in a specific phase (G0/G1, S, G2/M) and refers to at least four independent experiments. Statistical evaluation was performed by the student’s t-test. Histogram bars represent mean ± standard deviation of at least three independent replicates. d Western-blot analysis of cyclin A, cyclin E and p21 protein expression levels in U87MG cells upon miR-195-5p over-expression. e Viability assay in U87MG cells transfected with miR-195-5p inhibitor or control and treated with BRV or LCM at IC20. f Western-blot analysis of cyclin A, cyclin E and p21 protein expression levels in U87MG cells upon miR-195-5p depletion with miR-195-5p inhibitor (inh miR-195-5p). g Distribution of U87MG cells in the different phases of the cell cycle upon miR-195 depletion and treatments wit BRV or LCM at IC20. Data are expressed as percentage of cell in a specific phase (G0/G1, S, G2/M) and refers to at least four independent experiments. Statistical evaluation was performed by the student’s t-test. Histogram bars represent mean ± standard deviation of at least three independent replicates. h Western-blot analysis of cyclin A, cyclin E and p21 protein expression levels in U87MG cells upon miR-195-5p depletion with miR-195-5p inhibitor (inh miR-195-5p) and treatments wit BRV or LCM at IC20. (* = pval < 0.05)